David Hardy, MD

CRS:

JHU

Role:

Investigators

Dr. W. David Hardy formerly served as Senior Director of Evidence-based Practices, ACTG clinical research site (CRS) leader, MACS co-investigator and HIV/primary care provider at Whitman-Walker Health in Washington, D.C. He holds an Adjunct Professor of[HD1]  Medicine appointment at Johns Hopkins University School of Medicine in Baltimore.  He previously served as Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA. Just prior to joining Whitman-Walker, Dr Hardy was CMO for Calimmune, a California-based and funded (CIRM), translational science biotech investigating gene-modified CD4+ T cells and hematopoietic stem cells as a potential cure for HIV infection.

He received his medical degree from Baylor College of Medicine, Houston, TX and completed his residency in internal medicine at Harbor-UCLA Medical Center in Torrance, California. Early in the AIDS epidemic (1984-86), he completed a clinical fellowship in infectious diseases/immunology and clinical research at the UCLA School of Medicine under the direction of Dr Michael Gottlieb. Later he also completed a post-doctoral fellowship in molecular retrovirology with Irvin Chen, PhD at the David Geffen School of Medicine at UCLA focusing on development of retroviral vector delivery of gene therapy and vaccine applications.

Dr. Hardy has cared for persons with HIV infection since 1982 and conducted research on the disease since 1984. Initially, he focused on treatment and prevention of opportunistic infections and currently on antiretroviral agents, immunotherapies and hepatitis treatments as well as retroviral vector research and gene therapy.  Dr. Hardy currently serves on the Board of Directors of the American Academy of HIV Medicine and chair of the Education Committee. He served as editor-in-chief of the American Academy of HIV Medicine (AAHIVM) comprehensive textbook, Fundamentals of HIV Medicine for the HIV Specialist published in 2012 and 2016. Dr Hardy also served on the Board of Directors of the HIV Medicine Association (HIVMA) as an infectious diseases representative from 2011-2014.

  • CRS Leader At-Large, ACTG Performance Evaluation Committee (PEC)
    (Mar 2016-Nov 2018)
  • Co-chair, ACTG 5370 (2017)
  • Member, Viral Eradication and HIV Reservoirs (Cure) Transformative Science Group

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

A5337: Safety and Efficacy of Sirolimus for HIV Reservoir...

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More